Back to News
Market Impact: 0.2
Vistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock Up
Source: Nasdaq
Healthcare & Biotech
Vistagen Therapeutics announced preliminary data from the open-label extension of its PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder. The article provides no efficacy, safety, or financial details, limiting assessment of the clinical readout's significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
VTGN0.45
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum